Topoisomerase I Inhibitors Substituted with Carbohydrates
Researchers at Purdue University have developed a new topoisomerase I inhibitor that incorporates carbohydrate groups to increase solubility. The result is drug that is more bioavailable and stable, which comes with the added benefit of smaller doses acting more effectively. The synthetic route developed for these compounds is simple, versatile, and easily scalable. The newly synthesized compounds displayed potent anti-Top1 activity and ceased proliferation in transformed cells.
Carbohydrate-substituted indenoisoquinolines overcome common problems of solubility with this drug classTopoisomerase I is a proven target for cancer therapy
Cancer TreatmentMedical/HealthcarePharmaceuticalsDrug Development
Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
United States
None
美国
